Experts Mull How Life Sciences Firms Can Prep for ‘New Normal’

The COVID-19 pandemic has dramatically altered health care delivery patterns. Hospitals have had to exhaust their resources caring for COVID patients, while other important health care services, like cancer screening, have taken a back seat.

While the pandemic is not over, vaccination efforts continue and lockdown orders have eased, allowing experts the chance to look back at how the pandemic has affected the patient journey and what this means for a post-pandemic world. Health care stakeholders, including life sciences companies, are starting to ask about lessons learned and what changes need to be made to provide better patient support.

© 2024 MMIT
Freelance Reporter

Freelance Reporter Freelance Reporter

Related Posts

pills-and-cash
May 9

Specialty Drug Benefits Survey Spotlights Gene Therapy, Biosimilar Strategies

READ MORE
executives-and-chart
May 9

PBMs’ 1Q Earnings Calls Are All About Biosimilar, GLP-1 Programs

READ MORE
pills-and-bottles
May 9

High Price Tag, Accelerated Approval for New NASH Drug May Give Payers Pause

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today